Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | WNT3A | P56704 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6621631 | 0.83 | TSHR (0.65) | TSHRKDM4EATMHPGDPKM | |
| SCHEMBL4765745 | 0.81 | TSHR (0.73) | TSHRKDM4EATMHPGDPKM | |
| SCHEMBL12930767 | 0.81 | KDM4E (0.67) | TSHRKDM4EATMHPGDPKM | |
| SCHEMBL4824992 | 0.80 | NPSR1 (0.74) | TSHRKDM4EATMHPGDPKM | |
| SCHEMBL619634 | 0.79 | MAPK1 (0.78) | TSHRKDM4EATMHPGDPKM | |
| SCHEMBL4784460 | 0.78 | NPC1 (0.64) | TSHRATMHPGDPKMCTNNB1 | |
| SCHEMBL102971 | 0.77 | KDM4E (0.89) | TSHRKDM4EATMHPGDPKM | |
| SCHEMBL828491 | 0.77 | TSHR (0.67) | TSHRKDM4EATMHPGDPKM | |
| SCHEMBL624490 | 0.77 | TSHR (1.00) | TSHRKDM4EATMHPGDPKM | |
| SCHEMBL29410881 | 0.77 | TSHR (1.00) | TSHRKDM4EATMHPGDPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298383-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | NG RAYMOND | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298383-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, ESRRA | TSHR 888/4885KDM4E 1086/4885ATM 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.